神奇制药控股股东一致行动人张之君股份减持结果公告（2026年）

神奇制药控股股东一致行动人减持股份结果公告——投资者详细解读

报告要点梳理

减持主体：张之君先生，为公司控股股东贵州神奇控股（集团）公司的“一致行动人”，也是公司实际控制人张芝庭先生的亲弟弟。
减持前持股情况：减持计划实施前，张之君持有公司26,703,050股，占总股本4.9999%。股份来源于2018年12月通过协议转让取得。
减持计划：于2025年11月29日披露，张之君计划通过集中竞价及大宗交易方式减持不超过16,022,148股（占总股本3%），其中集中竞价不超过1%、大宗交易不超过2%。
减持结果：截至2026年3月20日收市，张之君累计减持12,340,700股，占总股本2.3107%，其中：
- 集中竞价方式减持5,340,700股，占总股本1%
- 大宗交易方式减持7,000,000股，占总股本1.3107%
减持后持股情况：张之君持有14,362,350股，占总股本2.6892%。
减持价格区间：5.84～6.55元/股
减持总金额：75,207,232.75元
一致行动人集团持股情况：张之君及其亲属和关联企业合计持股229,545,316股，占总股本42.98%。

对投资者的影响和重要事项

价格敏感信息：作为公司控股股东的一致行动人，张之君大额减持股份，可能影响市场对公司控股权稳定性的判断。虽然减持比例未超过公告计划的3%，但实际减持规模较大（超2.31%），且减持后其持股降至2.6892%。
减持方式：集中竞价和大宗交易均有大规模减持，表明张之君有较强套现意愿，可能引发市场对股价压力的担忧。
减持价格区间：减持价格为5.84～6.55元/股，接近公司近期股价区间，投资者应关注该价格带对二级市场价格的影响。
一致行动人集团仍为公司控股股东：减持后，一致行动人集团（包括张之君、贵州神奇控股、贵州迈吉斯投资管理、文邦英）合计持股占比约43%，控股地位依旧稳定。
计划合规性：本次减持严格按照此前披露计划实施，没有违反法律法规及承诺，减持比例未超计划，未提前终止。
公司控制权未发生变化：虽然张之君减持，控股股东及其一致行动人仍然掌控公司。

投资者需关注事项

大股东减持行为通常被市场视为价格敏感信息，可能引发投资者对公司前景及股价下行压力的担忧。
减持价格区间、减持规模及一致行动人剩余持股比例，是判断公司控股结构及未来股价走势的重要因素。
投资者应密切关注公司后续公告，警惕控股股东或一致行动人进一步减持行为。

结论

本公告显示，神奇制药控股股东一致行动人张之君已完成大规模减持，减持后控股地位仍稳定，但减持行为可能对公司股价产生压力。投资者应关注市场反应及公司后续控股结构变化。

免责声明

本文仅为信息披露及投资参考，不构成任何投资建议。投资者需自行判断相关风险，关注公司后续公告和市场动态。

Shanghai Shenqi Pharmaceutical: Detailed Summary of Shareholder Share Reduction Announcement

Key Points of the Report

Shareholder: Mr. Zhang Zhijun, an acting-in-concert party of the company’s controlling shareholder Guizhou Shenqi Holdings (Group), and brother of the actual controller, Mr. Zhang Zhiting.
Pre-Reduction Holdings: Before the reduction, Zhang Zhijun held 26,703,050 shares (4.9999% of total equity), acquired via block transfer in December 2018.
Reduction Plan: Announced on November 29, 2025, Zhang Zhijun planned to reduce up to 16,022,148 shares (not exceeding 3% of total equity), with no more than 1% via auction and 2% via block trade.
Reduction Results: By March 20, 2026, Zhang Zhijun reduced holdings by 12,340,700 shares (2.3107%). Of these:
- 5,340,700 shares (1%) via auction
- 7,000,000 shares (1.3107%) via block trade
Post-Reduction Holdings: Zhang Zhijun now holds 14,362,350 shares (2.6892%).
Reduction Price Range: RMB 5.84–6.55 per share
Total Reduction Amount: RMB 75,207,232.75
Acting-in-concert group holdings: Zhang Zhijun and related parties together hold 229,545,316 shares (42.98% of total equity).

Potential Price-Sensitive Information and Impact

Major Shareholder Reduction: Large-scale reduction by a major shareholder may affect perceptions of stability and trigger concerns of stock price pressure.
Reduction Methods: Both auction and block trades were used, indicating strong cash-out intent, which could affect market sentiment.
Reduction Price Zone: The reduction price zone is close to recent trading prices; investors should be aware of the possible impact on near-term stock price.
Group Still Controls Company: The acting-in-concert group still holds about 43% of total shares, maintaining control.
Compliance: Reduction followed pre-disclosed plans and regulatory requirements, no violations or premature termination.
No Change in Control: Despite the reduction, the controlling shareholder structure remains stable.

Investor Considerations

Large shareholder reductions are price-sensitive and may affect investor confidence and stock price.
Reduction size, price zone, and remaining holdings are key for assessing future shareholding structure and price performance.
Investors should monitor subsequent announcements and be alert to further reductions.

Conclusion

The announcement shows Shenqi Pharmaceutical’s acting-in-concert major shareholder Zhang Zhijun has completed a large-scale reduction. Despite the reduction, controlling status remains stable, but the reduction may put pressure on the share price. Investors should monitor market reaction and subsequent changes in shareholding structure.

Disclaimer

This article is for information disclosure and investment reference only and does not constitute investment advice. Investors should assess risks independently and follow subsequent company announcements and market dynamics.